Journals / Düzce Tıp Fakültesi Dergisi / 2014 / Cilt: 16 - Sayı: 1

ALANINE AMINOTRANSFERASE LEVELS AND MONOCYTE COUNT INDEPENDENTLY PREDICT 30-DAY OUTCOMES IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFULLY RESTORED CORONARY TIMI-3 FLOW BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION

Alanin Aminotransferaz Düzeyleri ve Monosit Sayısı Primer Perkutan Koroner Girişim ile Başarılı TIMI-3 Koroner Akım Sağlanan ST Yükselmeli Miyokard İnfarktüsünde 30 Günlük Sonuçları Bağımsız Olarak Öngörür

Pages
29–34
Publication Date
2014-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These parameters may provide new aspects, to identify the pathophysiology andprognosis of acute vascular events, which in turn may facilitate discovery of new treatmentmodalities

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate the relationship of various hematological and biochemical parametersbesides the cardiac enzymes with 30-day outcomes in patients with successfully restoredcoronary TIMI-3 flow by primary percutaneous coronary intervention (p-PCI).Materials and methods: Two hundred patients with ST elevation myocardial infarction(STEMI), with no history of prior myocardial infarction (MI), who underwent p-PCI and hadTIMI-3 flow, were enrolled, consecutively.
📊
Key Findings & Data:The primary endpoint of the study was defined asthe composite of death, fatal and non-fatal MI, target vessel revascularization andcerebrovascular event.Results: Only ALT concentration (OR: 1.010, 95% CI: 1.003-1.018, P = 0.008), monocytecount (OR: 1.002, 95% CI: 1.001 - 1.004, P = 0.005), hypertension (OR: 3.010, 95% CI: 1.081- 8.384, p = 0.035) and lower LVEF (OR: 0.926, 95% CI: 0.875 - 0.981, P = 0.008) wereindependent predictors of primary endpoint in multivariate logistic regression analysis.Conclusion: We found that elevated liver enzymes as determined by serum Alanineaminotransferase levels and monocyte count as well as hypertension and lower LVEFindependently predicted 30-day outcomes in patients with successfully restored coronary flowby p-PCI.
💡
Conclusion & Impact:These parameters may provide new aspects, to identify the pathophysiology andprognosis of acute vascular events, which in turn may facilitate discovery of new treatmentmodalities
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Miyokart enfarktüsü · Karaciğer enzimleri · Alanin aminotransferaz

Abstract

Aim: To investigate the relationship of various hematological and biochemical parametersbesides the cardiac enzymes with 30-day outcomes in patients with successfully restoredcoronary TIMI-3 flow by primary percutaneous coronary intervention (p-PCI).Materials and methods: Two hundred patients with ST elevation myocardial infarction(STEMI), with no history of prior myocardial infarction (MI), who underwent p-PCI and hadTIMI-3 flow, were enrolled, consecutively. The primary endpoint of the study was defined asthe composite of death, fatal and non-fatal MI, target vessel revascularization andcerebrovascular event.Results: Only ALT concentration (OR: 1.010, 95% CI: 1.003-1.018, P = 0.008), monocytecount (OR: 1.002, 95% CI: 1.001 - 1.004, P = 0.005), hypertension (OR: 3.010, 95% CI: 1.081- 8.384, p = 0.035) and lower LVEF (OR: 0.926, 95% CI: 0.875 - 0.981, P = 0.008) wereindependent predictors of primary endpoint in multivariate logistic regression analysis.Conclusion: We found that elevated liver enzymes as determined by serum Alanineaminotransferase levels and monocyte count as well as hypertension and lower LVEFindependently predicted 30-day outcomes in patients with successfully restored coronary flowby p-PCI. These parameters may provide new aspects, to identify the pathophysiology andprognosis of acute vascular events, which in turn may facilitate discovery of new treatmentmodalities

Özet

Amaç: Primer perkutan koroner girişim (p-PKG) ile başarılı TIMI-3 koroner akım sağlananhastalarda 30 günlük sonuçlar ile kardiyak enzimlerin yanında değişik hematolojik vebiyokimyasal parametreler arasındaki ilişkinin araştırılması amaçlandı.Materyal ve metod: Çalışmaya daha önceden miyokard infarktüsü geçirmeyen, p-PKGuygulanan ve TIMI-3 koroner akım sağlanan ST yükselmeli miyokart enfarktüslü (STYMI) 200hasta alındı. Çalışmanın birincil son noktası bileşik ölüm, ölümcül ve ölümcül olmayanmiyokard infarktüsü, hedef damara tekrar girişim ve serebrovasküler olaydı. Bulgular: Çok değişkenli analizde birincil son noktanın bağımsız öngörücüleri olarak sadecealanin aminotransferaz konsantrasyonu (OR: 1.010, 95% CI: 1.003-1.018, P = 0.008), monositsayısı (OR: 1.002, 95% CI: 1.001 - 1.004, P = 0.005), hipertansiyon (OR: 3.010, 95% CI: 1.081- 8.384, p = 0.035) ve düşük sol ventrikül ejeksiyon fraksiyonu (OR: 0.926, 95% CI: 0.875 0.981, P = 0.008) bulundu.Sonuç: Hipertansiyon ve düşük sol ventrikül ejeksiyon fraksiyonu kadar serum alaninaminotransferaz düzeyi olarak tanımlanan yükselmiş karaciğer enzimleri ve monosit sayısı pPKG ile başarılı koroner akım sağlanan hastalarda 30 günlük sonuçları bağımsız olarak öngördü.Bu parametreler akut vasküler olayların patofizyolojisini ve prognozunu anlamak için yeni bakışaçısı sağlayabilir.Bu da yeni tedavi seçeneklerinin bulunmasını kolaylaştırabilir

🔖

Cite This Article

ÇETİN, M., KOCAMAN, S. A., DURAKOĞLUGİL, M. E., ÇANGA, A., ÇİÇEK, Y., AKGÜL, Ö., GÜL, M., ERDOĞAN, T. (2014). ALANINE AMINOTRANSFERASE LEVELS AND MONOCYTE COUNT INDEPENDENTLY PREDICT 30-DAY OUTCOMES IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFULLY RESTORED CORONARY TIMI-3 FLOW BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION. Düzce Tıp Fakültesi Dergisi, Cilt: 16 - Sayı: 1, 29–34. https://ajindex.com/articles/420274

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Figueras J, Ferreira-Gonzalez I, Rizzo M, Alcalde O, Barrabes JA, Domingo E, et al. High incidence of TIMI flow 0 to I in patients with ST-elevation myocardial infarction without electrocardiographic lytic criteria. Am Heart J. 2009;158:1011- 7. Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45. Killip T, 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457-64.
  2. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-7. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932- 6. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634-53. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110:e506-10. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7-16.
  3. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
  4. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a